Autism Spectrum Disorder Trial, Recruiting NCT07302048 Sponsor: University Hospital, Brest Condition: Autism Spectrum Disorder
Back to Autism Spectrum Disorder

Autism Spectrum Disorder Trial, Recruiting

NCT07302048
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged from birth up to and including 24 years old (under 25 years of age)
  • People who have been formally diagnosed with an intellectual disability, either on its own or alongside autism spectrum disorder, a developmental disorder, or profound multiple disabilities, based on recognised international diagnostic systems (ICD-11 or DSM-5)
  • People whose pain has been assessed and confirmed as a probable or definite diagnosis by the MoDIDol team
  • People with a PGIC score of 3 or higher (confirm with trial site what this score means for the individual case)
  • People who live in or receive care in the French departments of Finistère, Côtes-d'Armor, or Morbihan
  • People whose parents, legal guardians, or holders of parental authority have provided written consent allowing data to be collected and used for research and publication
  • People who are covered by a French national health insurance scheme

Who may not be able to join:

  • People who live in or are cared for across more than three different residences or care settings
  • People whose parents or legal guardians do not have sufficient language or comprehension skills to give informed consent or to complete the study questionnaires

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Philippe J LE MOINE, MD, CHU de Brest

Phone: +332 98 22 39 56

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University Hospital, Brest
Registry
ClinicalTrials.gov
Start date
14 October 2025
Est. completion
20 April 2028

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Global Clinical Improvement at 6 months

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov